FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]

Para fines de investigación únicamente. Aviso completo →

Biblioteca de Stacks

Post-Surgery Recovery

Recovery & Healingintermediate

88

síntesis

88
Share
Péptidos

3

Promedio Diario mcg

7,000

Nivel

intermediate

Añadido

May 17, 2026

Visión General

The Post-Surgery Recovery stack is designed for accelerated healing following surgical procedures, combining tissue-repair peptides with immune support to address the dual challenges of wound healing and infection prevention. BPC-157 at standard dosing promotes angiogenesis and growth factor expression at surgical sites, while TB-500 is used at a higher loading dose (5000mcg) to maximize its systemic anti-inflammatory and tissue-migration effects during the critical early post-operative window. Thymosin Alpha-1 (Ta1) is the immune-support cornerstone of this stack. It is a 28-amino-acid peptide originally isolated from thymic tissue that enhances T-cell maturation, dendritic cell activation, and natural killer cell function. Ta1 is approved in over 35 countries under the brand name Zadaxin for hepatitis B/C and as an immune adjuvant. In the post-surgical context, it helps prevent opportunistic infections during the immunosuppressive period following anesthesia and surgical trauma, while also modulating inflammation to prevent excessive scarring. The synergy here is particularly elegant: BPC-157 and TB-500 handle the structural repair — new blood vessel formation, cellular migration, extracellular matrix deposition, and anti-inflammatory signaling — while Thymosin Alpha-1 ensures the immune system remains vigilant against post-surgical infections without triggering excessive inflammatory responses that could impair healing. This combination addresses the clinical reality that surgical recovery requires both tissue repair and immune competence, and that these processes must be balanced rather than maximized independently. This stack should only be used under physician supervision, ideally beginning 24-48 hours after surgery once initial hemostasis is established.

Protocolo de Dosis

BPC-157

Twice per day· subcutaneous

Leer más sobre BPC-157 →

250 mcg

por dosis

TB-500

2x/week· subcutaneous

Leer más sobre TB-500 →

5,000 mcg

por dosis

Thymosin Alpha-1

Every day· subcutaneous

Leer más sobre Thymosin Alpha-1 →

1,500 mcg

por dosis

Objetivos & Evidencia

Surgical recoveryWound healingImmune supportTissue repairScar reduction
Nivel de evidencia:Datos Humanos

Advertencias

  • Must be supervised by prescribing physician. BPC-157 and TB-500 were removed from FDA Category 2 (April 2026) but remain pending PCAC review — not legal to compound yet. Thymosin Alpha-1 remains FDA Category 2 (restricted) in the US (approved abroad in 35+ countries as Zadaxin).

Comments

Sign in to join the discussion

Aviso: Este stack es subido por la comunidad y solo tiene fines de investigación. Peptide Contacts no verifica la seguridad o eficacia de los stacks subidos. Siempre consulte a un profesional de la salud calificado antes de usar cualquier protocolo de péptidos.